ARCUTIS BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.62 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 255.34K shares, a 23.68% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 1.37M shares, a 27.60% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 99.68K shares, a 13.27% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 22.00K shares, a 60.00% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.35M shares, a 37.72% decline from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.77M shares, a 110.14% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.79M shares, a 20.82% decline from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.26M shares, a 16.37% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 255.34K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 1.62M shares 10-Q · filed 2026-08-05 | 1.72M shares derived: sum of 3 quarters · filed 2026-08-05 | 1.74M shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 1.37M shares 10-Q · filed 2026-05-06 | 1.47M shares derived: sum of 2 quarters · filed 2026-05-06 | 1.49M shares derived: sum of 3 quarters · filed 2026-05-06 | 1.82M shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 99.68K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 121.68K shares derived: sum of 2 quarters · filed 2026-02-25 | 456.22K shares derived: sum of 3 quarters · filed 2026-02-25 | 2.35M shares 10-K · filed 2026-02-25 |
| 2025-09-30 | 22.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | 356.54K shares derived: sum of 2 quarters · filed 2025-10-28 | 2.25M shares 10-Q · filed 2025-10-28 | 2.33M shares derived: sum of 4 quarters · filed 2025-10-28 |
| 2025-06-30 | 334.54K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 2.22M shares 10-Q · filed 2025-08-06 | 2.31M shares derived: sum of 3 quarters · filed 2025-08-06 | 2.37M shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 1.89M shares 10-Q · filed 2025-05-06 | 1.98M shares derived: sum of 2 quarters · filed 2025-05-06 | 2.03M shares derived: sum of 3 quarters · filed 2025-05-06 | 2.75M shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 88.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | 143.00K shares derived: sum of 2 quarters · filed 2025-02-25 | 861.42K shares derived: sum of 3 quarters · filed 2025-02-25 | 3.77M shares 10-K · filed 2025-02-25 |
| 2024-09-30 | 55.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 773.42K shares derived: sum of 2 quarters · filed 2024-11-06 | 3.68M shares 10-Q · filed 2024-11-06 | 3.86M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 718.42K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 3.62M shares 10-Q · filed 2024-08-14 | 3.81M shares derived: sum of 3 quarters · filed 2024-08-14 | 4.23M shares derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | 2.90M shares 10-Q · filed 2024-05-14 | 3.09M shares derived: sum of 2 quarters · filed 2024-05-14 | 3.51M shares derived: sum of 3 quarters · filed 2024-05-14 | 3.67M shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 184.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 607.00K shares derived: sum of 2 quarters · filed 2024-02-27 | 769.76K shares derived: sum of 3 quarters · filed 2024-02-27 | 1.79M shares 10-K · filed 2024-02-27 |
| 2023-09-30 | 423.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | 585.76K shares derived: sum of 2 quarters · filed 2023-11-03 | 1.61M shares 10-Q · filed 2023-11-03 | 1.74M shares derived: sum of 4 quarters · filed 2023-11-03 |
| 2023-06-30 | 162.76K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 1.19M shares 10-Q · filed 2023-08-08 | 1.32M shares derived: sum of 3 quarters · filed 2023-08-08 | 1.68M shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 1.02M shares 10-Q · filed 2023-05-09 | 1.15M shares derived: sum of 2 quarters · filed 2023-05-09 | 1.51M shares derived: sum of 3 quarters · filed 2023-05-09 | 2.00M shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 130.05K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 490.53K shares derived: sum of 2 quarters · filed 2023-02-28 | 974.00K shares derived: sum of 3 quarters · filed 2023-02-28 | 2.26M shares 10-K · filed 2023-02-28 |
| 2022-09-30 | 360.48K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 843.95K shares derived: sum of 2 quarters · filed 2022-11-08 | 2.13M shares 10-Q · filed 2022-11-08 | 2.35M shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 483.47K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 1.77M shares 10-Q · filed 2022-08-04 | 1.99M shares derived: sum of 3 quarters · filed 2022-08-04 | 2.73M shares derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | 1.29M shares 10-Q · filed 2022-05-05 | 1.51M shares derived: sum of 2 quarters · filed 2022-05-05 | 2.25M shares derived: sum of 3 quarters · filed 2022-05-05 | 2.97M shares derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | 216.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | 959.91K shares derived: sum of 2 quarters · filed 2022-02-22 | 1.68M shares derived: sum of 3 quarters · filed 2022-02-22 | 2.71M shares 10-K · filed 2022-02-22 |
| 2021-09-30 | 743.91K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 1.47M shares derived: sum of 2 quarters · filed 2021-11-04 | 2.49M shares 10-Q · filed 2021-11-04 | 2.60M shares derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | 721.86K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 1.75M shares 10-Q · filed 2021-08-05 | 1.85M shares derived: sum of 3 quarters · filed 2021-08-05 | 2.26M shares derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | 1.02M shares 10-Q · filed 2021-05-06 | 1.13M shares derived: sum of 2 quarters · filed 2021-05-06 | 1.54M shares derived: sum of 3 quarters · filed 2021-05-06 | 1.74M shares derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-12-31 | 105.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | 517.50K shares derived: sum of 2 quarters · filed 2021-02-16 | 715.63K shares derived: sum of 3 quarters · filed 2021-02-16 | 1.37M shares 10-K · filed 2021-02-16 |
| 2020-09-30 | 412.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 610.63K shares derived: sum of 2 quarters · filed 2020-11-05 | 1.26M shares 10-Q · filed 2020-11-05 | |
| 2020-06-30 | 198.13K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | 851.33K shares 10-Q · filed 2020-08-11 | ||
| 2020-03-31 | 653.20K shares 10-Q · filed 2020-05-12 | |||
| 2019-12-31 | 2.42M shares 10-K · filed 2021-02-16 | |||
| 2018-12-31 | 836.99K shares 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |